Search - tctmd.com

Displaying 221 - 240 of 285

Sort: Relevancy | Date

Presentation TCT 2016

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

Presenter: Antonio L. Bartorelli, Kenneth Chin, Ariel Furer

October 31, 2016

Presentation TCT 2016

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

Presenter: Michael J. Cowley, Franz-Josef Neumann, Joel Sainsous

October 31, 2016

Presentation TCT 2016

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

Presenter: Antonio L. Bartorelli, Kenneth Chin, Jens Wiebe

October 31, 2016

Presentation TCT 2016

TCT 57: Impact of Lesion Length on One-Year Outcomes of Absorb Bioresorbable Vascular Scaffolds

Presenter: Antonio L. Bartorelli, Kenneth Chin, Rony Lahoud

October 31, 2016

Presentation TCT 2016

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Michael Haude

October 31, 2016

Presentation TCT 2016

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Davide Capodanno

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Omega-3 Fatty Acids Can Aid Cardiac Remodeling After Acute MI

Leah Lawrence

August 02, 2016

News Daily News

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

Michael O'Riordan

August 01, 2016

News Daily News

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

Michael O'Riordan

August 01, 2016

News Daily News

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Michael O'Riordan

August 01, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2016

Shelley Wood

July 28, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2016

Shelley Wood

July 01, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

Advertisement

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

TCT 57: Impact of Lesion Length on One-Year Outcomes of Absorb Bioresorbable Vascular Scaffolds

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

TCTMD’s Top 10 Most Popular Stories for August 2016

The Bioresorbable Stent Story So Far: What Promise? What Price?

Omega-3 Fatty Acids Can Aid Cardiac Remodeling After Acute MI

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

TCTMD’s Top 10 Most Popular Stories for July 2016

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

TCTMD’s Top 10 Most Popular Stories for June 2016

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content